Acquiring Company
AbbVie Inc.
North ChicagoManufacturingBiotechnologyHealthcareHealth CareTherapeuticsNon ProfitPharmaceuticalBiopharmaDescription
AbbVie Inc. has announced its plan to acquire Cerevel Therapeutics Holdings, Inc. at a price of $45 per share. This acquisition follows a secondary stock offering by Cerevel that was organized by Bain and Pfizer. The market was misled by the misleading statements from Cerevel regarding this acquisition plan. Investors are encouraged to participate in the class action lawsuit regarding this matter.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie to acquire Cerevel for $45 per share (April 15, 2025)
- AbbVie acquires Cerevel Therapeutics for $45 per share (March 31, 2025)
- GSK completes acquisition of IDRx, Inc. to enhance precision therapeutics for treating gastrointestinal stromal tumours (February 24, 2025)
- OS Therapies completes acquisition of Advaxis assets from Ayala Pharmaceuticals (April 12, 2025)
- Roquette acquires IFF Pharma Solutions for growth (May 5, 2025)
- Apnimed acquires global rights to sulthiame (April 25, 2025)
Who to call at AbbVie Inc., and when
When AbbVie Inc. changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day AbbVie Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AbbVie Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AbbVie Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AbbVie Inc. makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.